Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.66 |
| ▸ | RAB9A | P51151 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | HSPA5 | P11021 | 9/20 | 0.65 |
| ▸ | HSPA2 | P54652 | 4/20 | 0.65 |
| ▸ | HSPA9 | P38646 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | METAP2 | P50579 | 1/20 | 0.62 |
| ▸ | METAP1 | P53582 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064879 | 0.88 | KCNK3 (0.62) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL23804606 | 0.82 | HSPA5 (0.78) | MEN1KMT2AHSPA5HSPA2HSPA9 | |
| SCHEMBL23804614 | 0.80 | HSPA5 (1.00) | ALDH1A1HSPA5HSPA2HSPA9SMN1; SMN2 | |
| SCHEMBL23804607 | 0.80 | HSPA5 (0.74) | HSPA5HSPA2HSPA9LMNASMN1; SMN2 | |
| SCHEMBL23804616 | 0.80 | HSPA5 (1.00) | ALDH1A1HSPA5HSPA2HSPA9SMN1; SMN2 | |
| SCHEMBL23804615 | 0.80 | HSPA5 (0.74) | HSPA5HSPA2HSPA9LMNASMN1; SMN2 | |
| SCHEMBL23804612 | 0.80 | HSPA5 (1.00) | ALDH1A1HSPA5HSPA2HSPA9SMN1; SMN2 | |
| SCHEMBL16011604 | 0.79 | ALDH1A1 (1.00) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL995829 | 0.78 | NPC1 (1.00) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL2628996 | 0.78 | NPC1 (0.76) | NPC1RAB9AMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101959515-B | Glucokinase activators | MERCK PATENT GMBH | 2013-06-12 | — | — | CN | claimed |
| CN-101959515-A | Glucokinase activators | MERCK PATENT GMBH | 2011-01-26 | — | — | CN | claimed |
| US-20100331338-A1 | Glucokinase Activators | MERCK PATENT GMBH (DE) | 2010-12-30 | — | — | US | claimed |
| EP-2244706-A1 | GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-11-03 | — | — | EP | claimed |
| WO-2009106203-A1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | claimed |
| EP-2244706-B1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| CN-101959515-B | Glucokinase activators | MERCK PATENT GMBH | 2013-06-12 | — | — | CN | disclosed |
| WO-2011145035-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | INDIAN INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-11-24 | — | — | WO | disclosed |
| CN-101959515-A | Glucokinase activators | MERCK PATENT GMBH | 2011-01-26 | — | — | CN | disclosed |
| US-20100331338-A1 | Glucokinase Activators | MERCK PATENT GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331338-A1 | Glucokinase Activators | MERCK PATENT GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331338-A1 | Glucokinase Activators | MERCK PATENT GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| EP-2244706-A1 | GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009106203-A1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106203-A1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331338-A1 | Glucokinase Activators | GCKR, HK1, GCK | NPC1 1277/4885RAB9A 2651/4885MEN1 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.